The repair of large non-unions in long bones remains a significant clinical problem due to high failure rates and limited tissue availability for auto-and allografts. Many cell-based strategies for healing bone defects deliver bone marrow stromal cells to the defect site to take advantage of the inherent osteogenic capacity of this cell type. However, many factors, including donor age and ex vivo expansion of the cells, cause bone marrow stromal cells to lose their differentiation ability. To overcome these limitations, we have genetically engineered bone marrow stromal cells to constitutively overexpress the osteoblast specific transcription factor Runx2. In the present study, we examined Runx2-modified bone marrow stromal cells, delivered via poly(caprolactone) scaffolds loaded with type I collagen meshes, in critically-sized segmental defects in rats compared to unmodified cells, cell-free scaffolds and empty defects. Runx2 expression in bone marrow stromal cells accelerated healing of critically-sized defects compared to unmodified bone marrow stromal cells and defects receiving cell-free treatments. These findings provide an accelerated method for healing large bone defects which may reduce recovery time and the need for external fixation of critically-sized defects.
Introduction
The repair of large bone defects in humans remains a significant clinical problem affecting approximately 600,000 people in the U.S. per year and costing upwards of 5 billion dollars annually 1, 2 . Despite successful bone healing with auto-and allografts, which are the most common clinical treatments for large non-unions, failure rates for these procedures remain unacceptably high. Autografts contain the appropriate cues for osteogenesis and elicit no immunogenicity, but donor site morbidity and pain affect as many as 30% of patients who have undergone a bone harvest from the iliac crest 3, 4 . Allografts address some of these sourcing issues but are further complicated by an increased risk of infection, poor revascularization and remodeling, and a high rate of fracture [5] [6] [7] . As an alternative approach for bone repair, cell-based regenerative medicine strategies are being developed to address the problems associated with current bone grafting procedures [8] [9] [10] [11] .
For successful repair and remodeling of large bone defects, a cell population capable of producing and remodeling bone must be present in the defect site. These cells can either be recruited from host tissues or delivered to the defect via surgical intervention. Bone marrow stromal cells (BMSCs) offer an attractive solution to cell sourcing for bone tissue engineering because they represent a multipotential cell population that contributes to the early stages of fracture healing in bone 12 . Human BMSCs can be isolated from bone marrow and delivered directly to a defect site to induce healing 13, 14 . BMSCs have the capability of differentiating into osteoblasts, among other cell types of the mesodermal lineage, and they mineralize constructs both in vitro and in vivo [15] [16] [17] [18] [19] . BMSCs also enhance bone healing in critically-sized orthotopic defects in rodents and large animals compared to treatment with a scaffold alone [20] [21] [22] [23] This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
autologous BMSCs seeded on bioceramic scaffolds. These implantations were initially reported in 2001, and a 6-7 year follow-up of each patient demonstrated that complete bone implant integration was achieved in all patients as determined by radiography and CT analysis 24, 25 .
The success of these cell-seeded constructs makes a compelling case for the use of autologous BMSCs in treating large bone defects in humans. However, multiple factors affect the differentiation of BMSCs into bone-producing osteoblasts. For example, in vitro expansion of BMSCs, a necessary step to obtain sufficient numbers for implantation, causes dedifferentiation and subsequent loss of mineralization capacity [26] [27] [28] . Furthermore, the mineralization potential and proliferation rate of BMSCs varies widely with individual donors and is significantly affected by donor age [29] [30] [31] . These complications with BMSC function suggest that the treatment of large bone defects with autologous BMSCs may not produce effective results for all patients. A strategy for overcoming these difficulties with BMSCs would provide great benefit to clinical bone healing.
To address these limitations with BMSCs, extensive work has focused on BMP delivery to host cells for the upregulation of osteoblastic differentiation 32-36 . However, low biostability and/or diffusion of these soluble factors away from a defect site makes the effective dosage for human BMP treatment very high, which in turn makes treatment with BMPs an expensive therapy 37 . Furthermore, as a soluble factor, diffusion of BMP away from the delivery site decreases the amount of bone formed in an implant and may lead to unregulated signaling in remote sites 38 . A recent retrospective study of complications due to spinal fusion in the U.S. demonstrated that BMP leads to 50% more complications in cervical spinal fusion compared to fusion without BMP 39 . As an alternative osteoinductive factor, we have focused on delivering the type 2 runt-related Cbfa1 gene Runx2, which encodes an osteoblast-specific transcription This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
factor that works intracellularly to upregulate a host of bone specific genes, including osteocalcin and collagen I 40-42 . Runx2 plays an important role in both bone development and bone remodeling/repair 43, 44 . Homozygous deletion of Runx2 in mice causes the formation of a completely non-mineralized, cartilaginous skeleton and results in immediate postpartum death 45, 46 . Mice heterozygous for Runx2 display a pathology similar to that observed in the skeletal disease cleidocranial displasia 46, 47 . In fact, the human disease, cleidocranial dysplasia, occurs as a result of genetic mutations in Runx2 [47] [48] [49] . The role of Runx2 as an osteoblastic transcription factor in human BMSCs has been demonstrated in vitro via DNA binding assays 50 Recently, our group and others have reported significant healing of critically-sized defects in a calvarial defect model treated with BMSCs engineered to overexpress Runx2 40, 56, 57 .
While these findings suggest the potential of Runx2 to promote healing of large non-unions in long bones, results obtained from calvarial defect studies do not necessarily translate to healing in long bones due to the involvement of the dura mater in healing cranial defects 58 . In the present study, we examined the effects of constitutive overexpression of Runx2 in BMSCs implanted in critically-sized segmental defects in rat femurs. This model provides a more rigorous test bed than a cranial defect by eliminating contributions to healing from the dura mater. This study is the first to investigate Runx2-modified BMCSs for the treatment of large This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. non-unions in long bones, providing better insight into the use of Runx2 as a cell-based gene therapy strategy for future clinical bone defect healing.
Materials and Methods

Cell harvest and isolation
Rat BMSCs were isolated from the hind legs of 7-week-old male Lewis rats (Charles River Labs) by commonly used methods 59, 60 . For each independent in vivo experiment performed, a separate cell harvest was generated by pooling the femoral and tibial cells from 1 to 2 rats. To isolate the cells, rats were euthanized by CO 2 inhalation (Georgia Tech IACUCapproved protocol), and the hind limbs removed, taking care to minimize bleeding and subsequent clotting. Surrounding soft tissue was removed from each bone, and the femurs and tibias were soaked in cell culture media consisting of αMEM (Invitrogen) + 10% fetal bovine serum (FBS, HyClone) + 1% penicillin/streptomycin (pen/strep, Invitrogen) + 0.3 μg/mL fungizone. The distal end of each bone was removed and the marrow was flushed from the diaphysis via centrifugation (2 min, 500g) into a sterile tube. The marrow pellet was then resuspended, and transferred to tissue culture-grade polystyrene (Corning). Three days after harvest, plates were rinsed twice in PBS to remove non-adherent hematopoietic cells, and fresh media was added. Media was changed every 3 days. When plates were 80-90% confluent, passage 0 cells were cryopreserved in 10% dimethylsulfoxide (DMSO) in FBS at -80 o C overnight, then transferred to liquid nitrogen for long term storage.
Scaffold fabrication
Medical grade polycaprolactone (PCL) scaffolds were manufactured in 9 mm thick sheets by fused deposition modeling (Osteopore International, Singapore). Scaffolds were reproducibly This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. cut from PCL sheets using dermal biopsy punches 4 mm in diameter (Miltex). MicroCT analysis was used to characterize the structural parameters of the scaffolds ( Figure 1A) . For in vivo studies, scaffold porosity was 81-85%, average pore size was 890 μm and average rod/strut thickness was 310 μm.
For all studies, scaffolds were cleaned in 70% ethanol for 30 minutes, rinsed 3 times in sterile water to remove ethanol, then soaked in PBS for 10-30 minutes prior to cell seeding. For in vivo studies, an additional step was added prior to scaffold sterilization for endotoxin removal.
For this step, scaffolds were rinsed in 70% ethanol for 4 days on a shaker plate, and ethanol was replaced once daily. Endotoxin levels were below the United States Food and Drug Administration's recommended 0.5 EU/mL, as determined by the LAL chromogenic assay (Cambrex).
To increase cell retention in PCL scaffolds, collagen meshes were produced within the scaffold pores by lyophilizing a collagen solution as previously described 61 . Briefly, a sterile solution of 1.5 mg/mL type I collagen (MP Biomedicals) was incubated within sterile PCL scaffolds at 37 o C for 30 minutes. Constructs were then frozen for 1 hour at -80 o C and lyophilized overnight to produce a fibrous mesh of collagen within the scaffolds.
Retroviral transduction
The Runx2 type II MASNSLF isoform was expressed via the pTJ66 vector as a single bicistronic mRNA sequence encoded by murine cDNA ( Figure 1B ). An internal ribosomal entry This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. efficiency 52, 53 . Empty pTJ66 vector, which was missing the Runx2 insert but still encoded the fusion protein, was used as an empty vector control.
To package Runx2 retrovirus, ΦNX helper cells, stably transfected with the Runx2 plasmid, were grown to sub-confluency in DMEM + 10% FBS + 1% pen/strep. Twenty four hours before the first viral harvest, media was changed and cells were transferred to a 32 o C incubator to minimize heat-induced viral degradation. To harvest virus, media supernatant was collected every 12 hours, filtered at 0.45 μm, snap frozen and stored at -80 o C.
To transduce primary BMSCs with Runx2 or empty-vector virus, bone marrow stromal cells were expanded to passage 3, then trypsinized and seeded into T-75 flasks at a density of 5,000 cells/cm 2 . One day after seeding into flasks, media was replaced with retrovirus supplemented with 0.4 μg/mL polybrene, as previously described 52 . Briefly, flasks were incubated with viral media at 32 o C for 15 minutes, then centrifuged at 1200g for 30 minutes.
Viral media was then replaced with fresh αMEM + 10% FBS + 1% pen/strep + 0.3 μg/mL fungizone, and cells were incubated at 37 o C. After 12 hours, a second transduction was performed. Two days after transduction, cells were trypsinized from flasks and seeded onto scaffolds or analyzed for eGFP expression by flow cytometry.
Cell seeding on scaffolds
Immediately prior to cell seeding, PCL-collagen scaffolds were pre-wet in PBS, then wicked on Kimwipes™ to remove excess fluid. Unmodified, Runx2-modified and emptyvector-modified cells (passage 4) were trypsinized and seeded at 500,000 cells per scaffold in 50 μL of media (25 μL per side). Scaffolds were placed in scaffold holders inside 24 well plates and incubated at 37 o C to allow cell attachment to the scaffolds. After 30 minutes of incubation,
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2 mL of media were added to each well for complete submersion of each scaffold. Media was changed every 3 days.
To ensure equal cell numbers were seeded onto all scaffolds, unmodified BMSCs were seeded onto PCL-collagen scaffolds, as described above, in three separate batches (n=4 scaffolds for each batch). Three days after cell seeding, DNA content on each batch of scaffolds was analyzed via Picogreen staining (Quant-iT TM Picogreen® dsDNA Assay Kit -Molecular Probes) as previously described 62, 63 . Briefly, constructs were rinsed in PBS, then frozen at -80 o C.
Thawed samples were dried in a Savant DNA120 SpeedVac Concentrator (Thermo Electron Corporation), and digested in 700 μg/mL Proteinase K (Promega) for 48 hours in a 45 o C water bath. Picogreen staining was used to quantify average DNA content/cell numbers on each batch of scaffolds. No differences in cell number were observed among groups (data not shown), confirming that cell seeding was reproducible across multiple batches.
Flow cytometry for transduction efficiency
For each in vivo study performed, a sample population of cells was harvested and analyzed for transduction efficiency. Briefly, 3 days after Runx2 or empty-vector transduction, cells were trypsinized (0.05% trypsin/EDTA -Invitrogen) and resuspended in PBS with 10% FBS. Cell suspensions were centrifuged for 5 minutes at 200-300g, resuspended in PBS and then passed through a 40 μm filter (BD Falcon). eGFP fluorescence was measured on a flow cytometer (Becton Dickinson, BD LSR II), and 10,000 events were measured for each sample. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Cell viability on PCL scaffolds was assessed using the Live/Dead kit (Invitrogen).
Unmodified and Runx2 modified cells were seeded onto PCL scaffolds with and without collagen meshes. Three days after seeding, constructs were rinsed 3 times in PBS, stained with 4 μM calcein and 4 μM ethidium homodimer in PBS for 45 minutes at room temperature. After staining, constructs were rinsed 3 times in PBS, and imaged on a confocal microscope (Zeiss LSM 510 NLO). LSM 5 Image Browser was used to stack groups of 2-dimensional image slices.
Segmental defect surgery
Femoral defects were created bilaterally as previously described 64 . Briefly, 13-to 15- week old female Lewis rats were anesthetized using isoflurane, and the hind limbs were shaved and swabbed with cycloheximide and alcohol to prepare the skin for incision. An anterior incision was made from the hip to the knee to allow blunt separation of the quadriceps muscles, exposing the femur. Before the defect was created, a modular fixation device was attached to the bone for mechanical support. The device consisted of two stainless steel plates affixed directly to the bone via screws and one polysulfone plate, which spanned the defect and was attached to the stainless steel plates ( Figure 1C ). Use of this modular system was advantageous for postmortem mechanical testing because the polysulfone plate could be removed before defect testing without removing the screws or stainless steel plates from the bone, thus avoiding any incidental damage to the repair tissue prior to testing. Furthermore, use of a polysulfone plate for support allowed non-invasive in vivo X-ray analysis of defects due to the low X-ray attenuation of polysulfone. After the fixation device was attached, an 8.0-mm segment of bone, amounting to 50.6 ± 1.9 mm 3 (as measured by post-mortem microCT analysis, n=8), was removed via bone saw. A scaffold was then press fit into the defect. Notches in the polysulfone plate, spaced 8.0mm apart, ensured each defect was consistently created the same length ( Figure 1C ). Muscle This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
was closed around the plate and defect using Vicryl sutures, and the skin was closed using sutures and wound clips.
For in vivo studies, five groups were tested: empty defect control (no scaffold or cells were placed in the defect) and PCL-scaffolds seeded with (i) unmodified BMSCs, (ii) Runx2modified BMSCs, (iii) empty vector-modified BMSCs or (iv) no cells (cell-free scaffolds).
These groups are outlined in Table 1 .
Following surgery, animals were given 3 daily doses of buprenorphine at 0.03 mg/kg for 2 consecutive days and 3 doses of 0.01 mg/kg on the third day to control pain. Animals were monitored daily for signs of pain and distress, progress of wound closure, regular eating habits and normal ambulation. A small percentage (< 8%) of rats developed infections in or around the surgery site, or experienced mechanical failure of the fixation device. These animals were removed from the study and euthanized, and any data collected from these animals was excluded.
Two weeks post surgery, when skin wounds had completely healed, animals were anesthetized with isoflurane and wound clips were removed. At 4, 8, and 12 weeks post-surgery, animals were anesthetized with isoflurane and the hind legs were scanned via radiography and microCT as described below. At 12 weeks post-surgery, animals were euthanized by CO 2 inhalation, and the femurs, along with surrounding muscle tissue, were harvested for postmortem microCT evaluation, histology, FTIR analysis and mechanical testing.
Radiography and microCT analyses
Every 4 weeks following surgery, 2-dimensional X-ray images of each sample were noninvasively obtained using an MX-20 Specimen Radiography System (Faxitron X-ray Corporation) to make gross morphological observations of bone formation in each defect site.
For X-ray analysis, animals were anesthetized in a gas chamber with 5% isoflurane and This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. maintained under anesthesia using 2% isoflurane flow into a face mask. Each hind leg of anesthetized animals was scanned for 15 s with an X-ray beam energy of 23 kV. X-ray images were blindly assessed for extent of bridging and assigned a bridging score from 0-5, as previously described 65 .
In addition to radiographic imaging, samples were non-invasively analyzed every 4 Bone volume was quantified using directly computed values.
Histological analysis
One sample from each cell group, with bone volume closest to the 12 week median bone volume for that group, was chosen as a representative sample for histological analysis.
Following euthanasia, these samples were immediately fixed in 10% neutral buffered formalin.
One day after fixation, soft tissue was removed, and specimens were placed in fresh formalin.
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Prior to embedding, fixed tissues were scanned ex vivo in formalin via microCT as described above to allow matching of histological sections with microCT slices. After scanning, specimens were dehydrated in a series of alcohols, cleared in xylene, and embedded in methyl methacrylate. Ground sections, 50-80 μm thick, were prepared by Wasatch Histo Consultants, Inc. (Winnemucca, NV) and stained using Sanderson's Rapid Bone Stain TM and a van Gieson counterstain 66 . Stained histological sections were then matched to thresholded microCT scans to confirm that microCT analysis was representative of mature bone.
FTIR spectroscopy
Explanted samples for FTIR analysis were wrapped in PBS-soaked gauze and frozen at - 
Mechanical testing
Samples for mechanical testing were explanted and wrapped in PBS-soaked gauze and frozen at -20 o C until use. Torsional properties for intact age-matched femora from Lewis rats were also measured. Mechanical testing was performed as previously described 64 . Briefly, samples were thawed in room temperature PBS and most of the soft tissue was removed, taking care not to mechanically disrupt tissue in the defect site. The ends of each bone were potted in This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Wood's metal up to the polysulfone plate and secured with pins into potting blocks. Blocks were loaded onto an ElectroForce® mechanical testing machine (Elf 3200, Bose) and the polysulfone plate was removed just before testing. Samples were loaded in torsion at a displacement rate of 3 o /s up to 360 o . Maximum torque before failure was recorded for each sample.
Statistical Analysis
Data from two independent studies was pooled, and a mixed model ANOVA was used to define experiment and individual animal as sources of error. This analysis was performed using the Hierarchical Linear Mixed Models function in Systat v12, which uses a Satterthwaite approximation to account for differences in sample sizes. For mechanical strength, the Tukey-Kramer method was used to determine differences between the pooled cell conditions (BMSC and Runx2) and empty defects, and the Pearson product-moment correlation coefficient was calculated for the correlation analysis. In addition, ridge regression using the Hoerl-Kennard model 67, 68 , was used to assess the relationship between torsion, bone volume and bridging score instead of the conventional linear multi-variate regression because bone volume and bridging score are not orthogonal. A p-value < 0.05 was considered significant.
Results
Runx2 expression and cell viability
To measure transduction efficiency of the Runx2 and empty-vector retroviruses, eGFP expression was measured via flow cytometry. Unmodified cells were used as a control population, and transduction efficiency of retrovirus-transduced cells was determined using the 2% of background method 69 . Runx2-modified cells showed 40% transduction efficiency as measured by eGFP expression compared to control cells (Figure 2A ). Empty vector-transduced cells showed 60% transduction efficiency (data not shown). These transduction efficiencies are in agreement with previous reports 60 .
Cell-seeded PCL scaffolds with and without collagen meshes were analyzed to determine cell viability and retention on the scaffolds. Live/Dead staining of cells on scaffolds 3 days postseeding shows that unmodified and Runx2-modified BMSCs are viable on PCL scaffolds both with and without collagen meshes. Scaffolds with collagen meshes promote an even distribution of cells throughout the pore volume of the PCL while scaffolds without meshes do not retain cells in the pore volume ( Figure 2B ). PCL scaffolds with collagen meshes were subsequently used for all in vivo studies, and "PCL" hereon refers to PCL with collagen mesh.
Radiography and microCT analysis
Immediately following surgery, animals were monitored several times daily for signs of pain or stress, regular eating habits, and normal ambulation. Within one week following surgery, signs of stress were minimal, regular eating had returned and normal ambulation using both hind limbs was restored.
To monitor bone formation in critically-sized defects, animals were anesthetized every 4 weeks and defects were scanned via X-ray and microCT. X-ray images show gross morphological changes in bone growth at the defect site over time. Whereas empty defects, PCL and BMSC groups showed minimal bone formation, Runx2 showed substantial increases in bone growth over time (Figure 3) . Representative X-ray images from each group are shown in Figure   3A , and the corresponding three-dimensional microCT reconstructions at 12 weeks are shown in Figure 3B . No differences were observed between unmodified BMSC and empty vector groups (data not shown). contained significantly more bone than unmodified BMSC defects (p < 0.05, n=8). However, at 12 weeks, bone volume in Runx2 defects was not significantly different compared to unmodified BMSC defects (p = 0.059) ( Figure 3C ). On average, the amount of bone formed in Runx2 treated defects at 12 weeks was about 50% of the total bone volume removed from the femur during surgery. It should be noted that the PCL scaffold occupies volume within each defect, which may contribute to the observed lack of difference between Runx2 and BMSC groups at 12 weeks. On the whole, this differential time course of bone formation in BMSC-and Runx2treated defects indicates that Runx2-modified BMSCs initially accelerate bone formation in critically-sized defects but that the osteogenic capacity of unmodified BMSCs eventually produces a similar level of bone as Runx2-modified BMSCs.
Histological analysis
To more fully characterize areas of high attenuation imaged by microCT, a representative sample from each cell group was subjected to histological analysis at 12 weeks. Prior to embedding, samples were scanned via microCT and thresholded in the same manner described above. Samples were then stained with Sanderson's Rapid Bone Stain TM , which distinguishes areas of mineralized bone from demineralized connective tissue and osteoid, revealing mineralized bone tissue in a red/pink color and demineralized osteoid in blue/green 70 This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
were thresholded in microCT and used as a measure of bone volume in Figure 3 , directly match areas of red/pink staining defined as mineralized bone tissue in the Sanderson's stain. Histology and CT images for Runx2 are shown in Figure 4 . Histology and CT images for BMSC also demonstrated this correlation (data not shown).
FTIR spectroscopic analysis of repair tissue
To determine the chemical composition of bone formed in the defects, tissue taken from the defect area of a representative sample from each group was analyzed by FTIR spectroscopy ( Figure 5 ). Spectra from native bone (positive control) contains all peaks expected for biologic apatite, including amide peaks for protein at 1700 and 1550 cm -1 , a small carbonate peak at 900 cm -1 , a broad phosphate peak for stretching vibrations at 900 -1200 cm -1 , and a phosphate doublet for bending vibrations at 525 -625 cm -1 60, 71, 72 . Cell-loaded samples having either unmodified BMSCs or Runx2-modified BMSCs displayed all of these bands ( Figure 5 ), indicating that the mineralized tissue in these defects was a biological, carbonate-containing hydroxyapatite. Cell-free PCL scaffolds also displayed most of these bands; however, the CO 3 and PO 4 (bending) peaks were less prominent in these cell-free samples as compared to native control bone or cell-loaded samples and the PO 4 doublet indicative of crystalline apatite was not evident. Finally, empty defect negative controls showed amide peaks and some phosphate deposits; however, CO 3 peaks and prominent PO 4 (stretching) peaks were not present, indicating that the tissue deposited in these samples did not have the chemical composition of native bone.
Mechanical strength of repaired defects is dependent on bridging
To assess mechanical functionality of the repair tissue present in critically-sized defects, was not significantly different between these two groups ( Figure 6B ). Stiffness and work to failure were calculated as the slope of the linear region (highlighted in Figure 6A ) and the area beneath the curve up to the maximum torque, respectively. No significant differences among experimental groups were observed for either of these parameters (data not shown). However, pooling of the data for cell-treated groups (Runx2 and BMSC) demonstrated a significant enhancement in maximum torque for cell-seeded scaffolds compared to empty defect negative controls ( Figure 6C ).
We hypothesized that mechanical strength is not only dependent on bone volume but also on defect bridging. Without full attachment (i.e. complete bridging) samples that have large bone volumes are expected to sustain low torque loads. To demonstrate that mechanical strength of the defects is not only dependent on bone volume but also on defect bridging, X-ray images for all samples were blindly assessed for their extent of bridging and assigned a bridging score from 0-5. Scoring criteria and representative X-ray images for each score are shown in Figure   7A This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
( Figure 7B ). In addition, a ridge regression analysis was performed with torsion as the dependent variable and bone volume and bridging score as independent variables. For this analysis, a Hoerl-Kennard ridge regression model was used instead of the conventional linear multi-variate regression because bone volume and bridging score are not orthogonal 67, 68 . This analysis yielded regression fit parameters (constant = 9.88, coefficient for bone volume = 0.46, coefficient for bridging score = 3.22, ridge parameter = 0.6) and an adjusted R 2 value of 0.41.
Test of significance indicated that this regression fit accurately describes the experimental data (p < 0.020). Although there are no significant differences in torsional strength between BMSCand Runx2-treated defects, a distribution of bridging scores from each group shows that Runx2modified defect scores are shifted towards fully bridged or nearly fully bridged (scores 4 and 5) compared to unmodified BMSC scores ( Figure 7C) . A Kruskal Wallis ANOVA by ranks demonstrates that the bridging score distribution for Runx2-treated defects is statistically different compared to that for BMSC-treated defects (p < 0.05).
Discussion
This study examined the effects of Runx2 expression in BMSCs on the repair of critically-sized segmental defects in rat femurs. Compared to scaffolds containing unmodified BMSCs, scaffolds alone, or empty defects, bone repair was accelerated in defects treated with all time points, cell-free and empty defects showed negligible bone formation. Taken together, this study demonstrates that Runx2 accelerates healing of large bone defects in vivo.
Runx2 has been described as a molecular switch for osteoblastic differentiation 43 , yet few studies have examined the potential use of Runx2 in healing critically-sized bone defects.
Three previous critically-sized orthotopic analyses of Runx2-modified BMSCs have been performed, all focusing on calvarial defects 40, 56, 57 . Although the cranial defect model provides relevant information regarding the healing of craniofacial defects, conflicting evidence regarding the role of periosteum, dura mater, and surrounding healthy bone tissue in cranial defect healing makes separation of host response from treatment effect difficult in a cranial model 58 . In particular, dura mater has been shown to have a significant effect on cranial defect healing 73 has also previously reported on Runx2 treatment of cranial defects. We have investigated BMSCs retrovirally tranduced with Runx2 and implanted on PCL scaffolds for 4 weeks in the rat calvarium. MicroCT analysis showed more bone in Runx2 treated defects, compared to unmodified controls and empty defects, following a 21 day pre-culture period. However, due to the open pore structure of our PCL scaffolds, cell-free scaffolds performed as well as Runx2engineered cell-loaded scaffolds in this study 40 . Given these differences, all 3 previous orthotopic studies comparing Runx2 transduced BMSCs to unmodified or LacZ transduced BMSCs showed a significant increase in bone formation due to Runx2 treatment, in agreement with the present study.
Although Runx2-modified BMSCs accelerated bone repair in critically-sized defects in this study, unmodified BMSCs eventually produced equivalent amounts of bone, pointing to the inherent ability of BMSCs to mineralize bone defects. Many studies have demonstrated successful healing of bone defects using unmodified BMSCs in both pre-clinical trials [20] [21] [22] , and recently, a pilot study of the implantation of autologous human BMSCs for repair of large bone defects in humans was reported by Marcacci et al. 2007 . In this study, 4 patients presented with large bone diaphysis defects, for which previous treatment with conventional surgical therapies had failed. Each patient underwent a BMSC harvest from the iliac crest, and the isolated cells were then cultured and seeded onto hydroxyapatite scaffolds custom made to fit the size and shape of the defects. For patients 1, 2, and 4, complete consolidation between the implant and host bone was radiographically evident between 5-7 months post-surgery, at which time external fixation devices were removed. For these patients, limb function was gradually regained within 8 months post-surgery. For patient 3, whose injury was more complex and involved the elbow joint, a custom made cast was fitted over the defect after removal of the Ilizarov apparatus at 8 The success of this study makes treatment with autologous BMSCs an attractive option for patients with large bone defects. However, a reduction in the time needed for external fixation is desirable, making the accelerated healing strategy presented in the current study relevant for clinical application.
The success of unmodified BMSCs for healing critically-sized defects in other preclinical studies may largely depend on the scaffold type used to deliver the cells. For example, all of the aforementioned studies which demonstrate successful healing (i.e. complete bridging) of segmental defects when treated with unmodified BMSCs employed the use of a hydroxyapatite scaffold to deliver the cells to the defect site. The osteoconductive properties of hydroxyapatite have been reviewed elsewhere 74 . In brief, calcium phosphate ceramics demonstrate bioactivity and osteoconductivity leading to rapid and strong osseointegration with host bone tissue when implanted into an orthotopic site. In fact, implantation of HA alone (without cells) has been shown to heal osteotomy defects in human patients 75 . In the present study, the use of a polymer scaffold, which is not inherently osteoconductive, in combination with the rigorous 8-mm segmental defect test bed, may explain why defects treated with unmodified BMSCs were not fully healed after 12 weeks. This result is in agreement with other studies that also show non-union of segmental defects treated with unmodified BMSCs when a non-ceramic scaffold is the delivery vehicle 76, 77 . Recent evidence suggests that the modification of PCL scaffolds with hydroxyapatite nanoparticles increases the bone forming response of cells seeded on the scaffolds 78 . In the present study, the rationale behind including a collagen matrix within PCL scaffolds was to increase the therapeutic load of cells delivered the defect site. It is
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A distinguishing aspect of this study over many reports of segmental defect healing is the use of mechanical testing to assess functionality of the defects. Many studies that report successful healing of bone defects rely solely on a combination of X-ray analysis and histological evaluation as a measure of defect healing. However, this approach does not provide functional information, which is necessary to fully evaluate the success of a given treatment strategy for bone healing 80 . Of the few groups that report mechanical testing analysis, the most common test method is torsion 36, 64, 81-84 . The current study demonstrates the importance of including mechanical testing analysis to evaluate bone healing because, in this case, the significant differences in bone volume measured by microCT did not translate to significant differences in torsional strength between Runx2 and BMSC treated defects at 12 weeks postimplantation. However, we did observe that samples with greater bridging scores generally had greater strength than samples with lower bridging scores. Longer time points may be necessary to fully evaluate the effects of gene-and cell-based therapies for bone repair in this model. Finally, the present results argue that functional mechanical evaluation of bone defects should be used in conjunction with other methods for complete analysis of both bone mass and bone quality.
In summary, we have demonstrated accelerated bone healing in critically-sized femoral defects due to treatment with Runx2-modified BMSCs delivered on synthetic polymer scaffolds.
Although Runx2 modification did not enhance defect bridging or biomechanical function after 12 weeks compared to unmodified BMSCs, this genetic modification strategy specifically upregulates osteoblastic differentiation thereby offering an accelerated means of bone formation This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
28.
Yeon Lim, J., Jeun, S.S., Lee Table 1 . Outline of experimental groups for in vivo segmental defects. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. . FTIR spectra demonstrate that the chemical composition of the repair tissue for cell-treated defects is similar to that of native bone. Bands characteristic of biologic hydroxyapatite, namely a small carbonate peak at 855 -890 cm -1 , a broad phosphate peak at 900 -1200 cm -1 , and a phosphate doublet at 525 -625 cm -1 , are present in Runx2-modified and unmodified BMSC-treated defects, as well as native bone. Cell-free scaffold spectra contain peaks that are shifted compared to native bone, and empty defects do not contain characteristic peaks.
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